Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by priceless2on Nov 12, 2019 12:09pm

211 Views

Post# 30340330

RE:RE:RE:RE:RE:RE:RE:Zenith update

CDN $1.00..... All private placements have been at $2 USD, based on the Enterprice Value which IMO is extremely low , What is the EV going to be once Zen 3694 is approved it is working for extending life for those with NMCRPC, If you can get Zenith for $1 CDN get as many as you can

Bullboard Posts

Catch up with companies that got a Stanley Cup Playoffs boost